Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Sells $125,240.44 in Stock

Tricida, Inc. (NASDAQ:TCDAGet Rating) major shareholder Brian M. Isern sold 11,804 shares of Tricida stock in a transaction that occurred on Thursday, April 28th. The shares were sold at an average price of $10.61, for a total transaction of $125,240.44. Following the completion of the sale, the insider now owns 770,496 shares of the company’s stock, valued at $8,174,962.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

NASDAQ TCDA opened at $9.73 on Friday. The company has a debt-to-equity ratio of 584.92, a quick ratio of 4.94 and a current ratio of 4.94. Tricida, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $12.45. The stock has a market cap of $539.01 million, a PE ratio of -2.83 and a beta of 1.10. The firm’s fifty day moving average price is $9.06 and its two-hundred day moving average price is $8.30.

Tricida (NASDAQ:TCDAGet Rating) last issued its quarterly earnings data on Tuesday, March 29th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.21). During the same period in the prior year, the company earned ($1.09) EPS. As a group, sell-side analysts predict that Tricida, Inc. will post -2.35 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on TCDA. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of Tricida in a research report on Wednesday, March 30th. Zacks Investment Research downgraded shares of Tricida from a “buy” rating to a “hold” rating in a research report on Thursday, January 20th. Finally, The Goldman Sachs Group started coverage on shares of Tricida in a research report on Tuesday, April 12th. They set a “buy” rating and a $25.00 price objective for the company.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Dorsey Wright & Associates purchased a new stake in Tricida in the 1st quarter valued at about $30,000. Sciencast Management LP purchased a new stake in shares of Tricida during the 1st quarter valued at $190,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Tricida by 92.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,270 shares of the company’s stock valued at $27,000 after buying an additional 1,569 shares in the last quarter. Belvedere Trading LLC raised its position in Tricida by 11,449.0% in the 1st quarter. Belvedere Trading LLC now owns 22,867 shares of the company’s stock worth $269,000 after purchasing an additional 22,669 shares during the period. Finally, Norges Bank purchased a new position in Tricida in the 4th quarter worth $437,000. Hedge funds and other institutional investors own 88.47% of the company’s stock.

Tricida Company Profile (Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Featured Articles

Insider Buying and Selling by Quarter for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with's FREE daily email newsletter.